Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06414915
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
Sponsor:
National Cancer Center China
Organization:
National Cancer Center China